This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
NeuroMetrix, Inc. (Nasdaq: NURO),
www.neurometrix.com, today said it plans to issue its 2012 full year and fourth quarter financial results before the opening of the market on February 19, 2013. The Company will host a conference call at 8:00 a.m., Eastern Time on February 19, 2013 to discuss its financial results as well as business developments affecting the Company.
The conference call may be accessed in the United States by dialing 866-825-3308 and using the confirmation code 23668017. Internationally, the conference call may be accessed by dialing 617-213-8062 and using the same confirmation code. The earnings press release and accompanying condensed financial statements will be accessible from the Company's website at
www.neurometrix.com under the "Investors" tab.
A replay of the conference call will be available starting two hours after the call by dialing 888-286-8010, domestically and 617-801-6888, internationally. The confirmation code to access the replay is 85981713. The replay will be available for three months after the conference call.
NeuroMetrix is an innovative medical device company that develops and markets home use and point-of-care devices for the treatment and management of diabetic neuropathies, which affect over 50% of people with diabetes. If left untreated, diabetic neuropathies trigger foot ulcers that may require amputation, cause disabling chronic pain, and increase the risk of falling in the elderly. The annual cost of diabetic neuropathies has been estimated at $14 billion in the United States. The company’s products are used by physicians and managed care organizations to optimize patient care and reduce healthcare costs. The company markets the NC-stat
® DPNCheck™ device, which is a rapid, accurate, and quantitative point-of-care test for diabetic neuropathy. This product is used to detect diabetic neuropathy at an early stage and to guide treatment. The company also markets the SENSUS™ Pain Management System for treating chronic pain, focusing on physicians managing patients with painful diabetic neuropathy. The company has additional therapeutic products in its pipeline. For more information, please visit